Down-regulation of RORA gene expression in the blood of multiple sclerosis patients

Hum Antibodies. 2018;26(4):219-224. doi: 10.3233/HAB-180341.

Abstract

Multiple sclerosis (MS) is an autoimmune disease characterized by recurrent episodes of demyelination and loss of oligodendrocytes. The demyelination process is caused by various subsets of CD4+ T cells with a Th1 and Th17 phenotype. The retinoid acid-related orphan receptor A (RORA) is expressed in Th17 cells and promote Th17 differentiation. In this study, we compared the expression level of RORA gene in the blood of 50 relapsing-remitting MS (RRMS) patients who were treated with IFN-β and 50 healthy controls by TaqMan Quantitative Real-Time PCR.We found that RORA expression was significantly down-regulated in MS patients compared with controls (P= 0.006). However, there was no significant correlation between RORA gene expression and Kurtzke Expanded Disability Status Scale (EDSS). Our findings suggest a possible contribution of IFN-β in the downregulation of RORA. In addition, RORA downregulation may be a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.

Keywords: IFN-β; Multiple sclerosis; RORA.

MeSH terms

  • Adult
  • Age of Onset
  • Case-Control Studies
  • Disability Evaluation
  • Down-Regulation
  • Female
  • Humans
  • Interferon-alpha / therapeutic use
  • Interferon-beta / metabolism
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / blood*
  • Multiple Sclerosis, Relapsing-Remitting / genetics
  • Nuclear Receptor Subfamily 1, Group F, Member 1 / blood*
  • Nuclear Receptor Subfamily 1, Group F, Member 1 / genetics
  • Real-Time Polymerase Chain Reaction
  • Th17 Cells

Substances

  • Interferon-alpha
  • Nuclear Receptor Subfamily 1, Group F, Member 1
  • RORA protein, human
  • Interferon-beta